NOVEL TREATMENT APPROACHES IN REACTIVE ARTHRITIS: CLINICAL AND CYTOKINE RESPONSES TO IGURATIMOD 25 MG COMPARED WITH BIOLOGIC AND CONVENTIONAL THERAPIES

Please use this identifier to cite or link to this item: http://repo.tma.uz/xmlui/handle/1/2635

Full metadata record

DC Field	Value	Language
dc.contributor.author	Javohir Mullokulov., Khalmurad Akhmedov
dc.date.accessioned	2025-12-15T05:02:28Z
dc.date.available	2025-12-15T05:02:28Z
dc.date.issued	2025
dc.identifier.citation	Toshkent	en_US
dc.identifier.uri	http://repo.tma.uz/xmlui/handle/1/2635
dc.description.abstract	Reactive Arthritis (ReA) is an immune-mediated form of spondyloarthritis, often triggered by genitourinary or gastrointestinal infections. Current therapeutic strategies rely mainly on NSAIDs and cs-DMARDs, with biologics reserved for refractory disease. However, limited progress has been made in exploring novel targeted agents. Iguratimod 25 mg, an oral immunomodulatory drug approved for rheumatoid arthritis in Asia, has demonstrated anti-inflammatory and cytokine-suppressive properties, but evidence in ReA is scarce	en_US
dc.language.iso	en	en_US
dc.subject	To evaluate the clinical efficacy and cytokine-modulating effects of Iguratimod 25 mg in patients with Reactive	en_US
dc.title	NOVEL TREATMENT APPROACHES IN REACTIVE ARTHRITIS: CLINICAL AND CYTOKINE RESPONSES TO IGURATIMOD 25 MG COMPARED WITH BIOLOGIC AND CONVENTIONAL THERAPIES	en_US
dc.type	Thesis	en_US
Appears in Collections:	Articles

Files in This Item:

File	Description	Size	Format
TermezConference.pdf	NOVEL TREATMENT APPROACHES IN REACTIVE ARTHRITIS: CLINICAL AND CYTOKINE RESPONSES TO IGURATIMOD 25 MG COMPARED WITH BIOLOGIC AND CONVENTIONAL THERAPIES	919.61 kB	Adobe PDF	View/Open

DSpace JSPUI